Abelacimab, formerly known as MAA868, represents a groundbreaking approach to managing thrombosis. This antiplatelet agent is a selective monoclonal protein that blocks the integrin αIIbβ3, a essential player in https://anitanloi454367.activoblog.com/52438121/abelacimab-maa868-a-deep-analysis-into-the-new-blood-clot-treatment